# GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers

> **NCT06076070** · — · UNKNOWN · sponsor: **Regina Elena Cancer Institute** · enrollment: 10 (estimated)

## Conditions studied

- Sarcoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06076070
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-25
- **Primary completion:** 2024-05-25
- **Final completion:** 2024-05-25
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06076070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06076070, "GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06076070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*